• ANKFY1 Links Endosomes to Phagophore Expansion

  2026-09-21

  The 2024 Cell Discovery study identifies ANKFY1 as an endosome-localized ATG2A-binding protein that connects PI3P-rich endosomes with growing phagophores. Its results support endosomes as an additional lipid source for autophagosome biogenesis and clarify how membrane contact-site proteins may coordinate lipid transfer during autophagy.

• Machine Learning for Senolytic Discovery

  2026-09-20

  The reference study demonstrates that machine-learning models trained only on published screening data can identify senolytic candidates despite small, heterogeneous datasets. Experimental validation of ginkgetin, periplocin, and oleandrin shows how literature mining can reduce early-stage screening costs while preserving the need for context-specific selectivity testing.

• JC-1 Mitochondrial Membrane Potential Assay Kit Workflow

  2026-09-19

  Turn mitochondrial depolarization into a quantitative red-to-green signal for apoptosis assay development, drug screening, and mitochondrial function analysis. This workflow connects the JC-1 readout to hypoxia-activated cancer therapy research while emphasizing controls, normalization, and troubleshooting.

• DFCP1 Controls ATGL-Driven Lipid Droplet Lipolysis

  2026-09-18

  The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of starvation-induced lipid droplet catabolism. Its central mechanistic finding is that DFCP1 recruits ATGL to lipid droplets while limiting ATGL exchange, thereby restraining lipolysis rather than simply changing droplet abundance.

• Palomid 529 (P529) for PI3K/Akt/mTOR Studies

  2026-09-18

  Palomid 529 (P529) enables pathway-focused cancer research by simultaneously interrogating mTORC1 and mTORC2, with applications spanning ESCC resistance, tumor angiogenesis inhibition, and radiotherapy enhancement. This guide translates the RCN2–PPP2CA–PI3K-AKT findings into practical dosing, combination, readout, and troubleshooting workflows.

• RBMS1 Loss Enables Immunity in Triple-Negative Breast Cancer

  2026-09-17

  The reference study identifies RBMS1 as an immune-suppressive RNA-binding protein that maintains PD-L1 stability in immune-cold triple-negative breast cancer through B4GALT1-dependent glycosylation. Its findings connect post-transcriptional RNA control with checkpoint regulation and show why RBMS1 depletion may improve cytotoxic T-cell, checkpoint-blockade, and CAR-T responses in experimental models.

• Tobramycin: Reading MIC Data Mechanistically

  2026-09-17

  Tobramycin is an aminoglycoside antibiotic and bacterial protein synthesis inhibitor widely used in Gram-negative microbiology research. This article moves beyond routine workflows to show how historical MIC methods, physicochemical properties, and resistance phenotypes can be integrated into stronger mechanistic assay decisions.

• IRG1–Itaconic Acid Control of TBK1 Signaling

  2026-09-16

  A 2025 Cell Reports study identifies the IRG1–itaconic acid axis as a metabolic feedback mechanism that restrains TBK1-driven type I interferon production by modifying TBK1 at Cys605. The work also introduces itaconic acid-derived compounds ITA-5 and ITA-9 as candidate inhibitors for limiting IFN-I-associated hyperinflammation.

• Bestatin hydrochloride: Applied Research Workflows

  2026-09-16

  Bestatin hydrochloride, also called Ubenimex, connects aminopeptidase biology with practical workflows for angiogenesis, tumor, and neuronal peptide-processing studies. This guide emphasizes target-engagement controls, assay-specific dosing, and troubleshooting strategies that help distinguish enzyme inhibition from downstream cellular effects.

• Protease Inhibitor Cocktail for DFCP1–ATGL Assays

  2026-09-15

  A practical, mechanistic guide to using a Protease Inhibitor Cocktail when studying starvation-driven DFCP1–ATGL lipid droplet lipolysis. Learn how EDTA, extraction timing, and assay compatibility influence protein-interaction and lipase readouts.

• Bestatin (Ubenimex) Research Workflows

  2026-09-15

  Bestatin (Ubenimex) combines selective aminopeptidase inhibition with a practical chemical-genetics use case in jasmonate signaling. This guide translates that evidence into enzyme, cell-based, multidrug-resistance, apoptosis, and plant workflows while emphasizing controls, solubility, and assay interpretation.

• PP 2 (AG 1879): Mapping Src-to-ROCK Signaling

  2026-09-14

  PP 2 (AG 1879) offers translational researchers a focused way to interrogate Src-family kinase signaling across cancer, immune, and cell-morphology models. This article connects its Lck and Fyn activity with the PA-Src-FAK-RhoA/ROCK pathway, outlines validation strategies, and defines where the tool informs mechanism rather than clinical efficacy.

• SB525334: Selective TGF-beta1 Receptor Inhibitor

  2026-09-14

  SB525334 is a selective TGF-beta1 receptor inhibitor that targets ALK5 and suppresses Smad2/3 signaling. Its biochemical selectivity and reported antifibrotic activity make it a useful research tool for fibrosis research, renal disease models, and controlled studies of TGF-beta signaling.

• LRPPRC Inhibition and Dasatinib: Dual OXPHOS Blockade

  2026-09-13

  The reference study identifies dasatinib as a synergistic partner for LRPPRC inhibition and explains the effect through complementary suppression of nuclear- and mitochondrial genome-encoded OXPHOS programs. Its screening and validation strategy supports biomarker-guided combination research in LRPPRC-high tumors, while remaining preclinical and dependent on careful model and assay selection.

• ARCA Cy5 EGFP mRNA (5-moUTP) Workflow Guide

  2026-09-12

  Build a dual-readout workflow that separates mRNA uptake from productive translation in mammalian cells. This guide combines fluorescence microscopy, flow cytometry, and delivery-system benchmarking with practical controls and troubleshooting.

554 records 4/37 page Previous Next 12345 下5页 Last page